Evidence map›Paper›PMID 30096040›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2019

Residual cyclooxygenase activity of aspirin-acetylated COX-2 forms 15 R-prostaglandins that inhibit platelet aggregation.

Juan A Giménez-Bastida, William E Boeglin, Olivier Boutaud, Michael G Malkowski, Claus Schneider

Open access · bronzeAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Unusual and atypical cyclooxygenase reactions.The Journal of biological chemistry · 2026
    Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Unveiling the pharmacological potential ofFood science & nutrition · 2024
    Article
  12. Review
  13. An Updated Review on Glycoprotein IIb/IIIa Inhibitors as Antiplatelet Agents: Basic and Clinical Perspectives.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023
    Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Targeting Lipid Peroxidation for Cancer Treatment.Molecules (Basel, Switzerland) · 2020
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Juan A Giménez-BastidaDivision of Clinical Pharmacology, Department of Pharmacology, Vanderbilt University Medical School, Nashville, Tennessee, USA.
William E BoeglinDivision of Clinical Pharmacology, Department of Pharmacology, Vanderbilt University Medical School, Nashville, Tennessee, USA.
Olivier BoutaudDivision of Clinical Pharmacology, Department of Pharmacology, Vanderbilt University Medical School, Nashville, Tennessee, USA.
Michael G MalkowskiDepartment of Structural Biology, University of Buffalo, The State University of New York, Buffalo, New York, USA.
Claus SchneiderDivision of Clinical Pharmacology, Department of Pharmacology, Vanderbilt University Medical School, Nashville, Tennessee, USA.
Vanderbilt University · USVanderbilt University Medical Center · USUniversity at Buffalo, State University of New York · US

Funding

Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Exploring New Virulence Factors of the Oral Spirochete Treponema denticolaR01DE023080 · NIDCR · VIRGINIA COMMONWEALTH UNIVERSITY · PI Chunhao Chris Li · 2013 to 2026
$5.2M
Convergence of the COX-2 and 5-lipoxygenase pathwaysR01GM076592 · NIGMS · VANDERBILT UNIVERSITY · PI SCHNEIDER, CLAUS · 2007 to 2021
$4.0M
Structure and Dynamics of Cyclooxygenase Catalysis and InhibitionR01GM115386 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MALKOWSKI, MICHAEL G · 2015 to 2018
$1.5M
Novel Pathways of Eicosanoid MetabolismR01GM118412 · NIGMS · VANDERBILT UNIVERSITY · PI SCHNEIDER, CLAUS · 2017 to 2020
$1.3M
American Heart Association-American Stroke Association 16POST30690001NIDCR NIH HHS R01 DE023080NIDDK NIH HHS P30 DK058404NIGMS NIH HHS R01 GM076592NIGMS NIH HHS R01 GM115386NIGMS NIH HHS R01 GM118412
6 · The paper itself

Abstract

Aspirin (acetylsalicylic acid) inhibits prostaglandin (PG) synthesis by transfer of its acetyl group to a serine residue in the cyclooxygenase (COX) active site. Acetylation of Ser530 inhibits catalysis by preventing access of arachidonic acid substrate in the COX-1 isoenzyme. Acetylated COX-2, in contrast, gains a new catalytic activity and forms 15 R hydroxy-eicosatetraenoic acid (15 R-HETE) as alternate product. Here we show that acetylated COX-2 also retains COX activity, forming predominantly 15 R-configuration PGs (70 or 62% 15 R, respectively, determined using radiolabeled substrate or LC-MS analysis). Although the K

Indexed as

15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic AcidAcetylationAspirinCells, CulturedChromatography, LiquidCyclooxygenase 2DinoprostoneHumansHydroxyeicosatetraenoic AcidsKineticsLeukocytesMass SpectrometryPlatelet Aggregation15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid15-hydroxy-5,8,11,13-eicosatetraenoic acidAspirinCyclooxygenase 2DinoprostoneHydroxyeicosatetraenoic AcidsPTGS2 protein, humanarachidonic acidbiosynthesisleukocytesstereocontrol

Identifiers

PMID30096040
PMCPMC6355089
OpenAlexW2887196719

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.